MPS IVA Clinical Trial
Official title:
A Proof of Concept Study to Evaluate the Safety and Efficacy of Voxzogo (Vosoritide) for the Treatment of Growth Deficits in MPS IVA and VI
This is a Phase I/II, single arm, open label study of vosoritide therapy provided subcutaneously at 15 ug/kg/day for 48 weeks to 6 patients with MPS IVA or VI. Prior to enrollment in the interventional arm of study, subjects will be followed for a minimum of 24 weeks to gather information on safety profiles and determine annualized growth velocity. The primary study endpoint is the determination of safety and tolerability of daily vosoritide treatment in MPS. Exploratory endpoints include changes in linear and segmental growth as well as biomarkers of growth and bone metabolism.
Status | Recruiting |
Enrollment | 6 |
Est. completion date | December 2026 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years to 10 Years |
Eligibility | Inclusion Criteria: - Age >= 5 years and < 10 years - Tanner stage 1 - Clinical Diagnosis of MPS IVA or VI Subjects will be stratified into 2 groups: - MPS IVA (3 patients) - MPS VI (3 patients) - MPS Diagnosis Confirmed by either: 1. Demonstration of 2 pathogenic or likely pathogen mutations (or homozygous for single mutation) and elevated GAG (either before or during ERT treatment), OR 2. Demonstration of diagnostic enzyme deficiency, elevated GAG (either before or during ERT treatment), and a normal second sulfatase - Currently receiving ERT [elosulfase alfa (Vimizim®) or galsulfase (NAGLAZYME®)] for minimum of 12 months prior to study entry - HSCT greater than 3 years before entry - Height Z-score <-2.0 or less than 2 cm change in height velocity over the last 1 year - Willing to consent to the study and comply with all study procedures and assessments - Able to stand independently without hand support for minimum of one minute - Guardians able to successfully administer investigational drug daily/SQ Exclusion Criteria: - ERT naïve - Poor compliance with ERT (<75% in 6 month period) - Diagnosis with growth hormone deficiency (defined by IGF-1 SDS <-1.0 according to age, gender and tanner stage) - Hypothyroidism, untreated (TSH >4.0 mU/L) - Receiving or has received growth hormone therapy, IGF-1 therapy, anti-TNF alpha therapy, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, diuretics, beta-blockers, calcium channel blockers, cardiac glycosides, systemic anticholinergic agents, any medication that may impair or enhance compensatory tachycardia, diuretics or other drugs known to alter renal or tubular function within the previous 6 months. - Receiving or has previously received a GnRH analog (e.g. leuprolide acetate, histrelin) - History of malignancy - History of chronic inflammatory condition not related to MPS - History of conditions/medical therapies that might affect the interpretation of growth results such as anemia, celiac disease, diabetes, inflammatory bowel disease, and cystic fibrosis - QTC (Fridericia) > 450 msec - Malnutrition (BMI <5th percentile) - History of gene therapy - Concurrent participation on an investigational drug trial - Investigational drug washout minimum of 5 half-lives of the drug or 1 month whichever is longer - Previous or current treatment with the investigational drug (vosoritide) - Known or suspected allergy to the investigational drug (vosoritide) - Bone fracture within the previous 6 months - Skeletal surgery within the previous 6 months, or anticipated significant surgery (in the view of the investigator) during course of the study - Any history of bone lengthening surgeries or spine fixation surgery - Spine curvature (scoliosis) on previous x-ray greater than 25 degrees - Untreated severe sleep apnea - History of chronic renal insufficiency, defined previously as an eGFR <60 mL/min/1.73m2 - Illness that could affect blood pressure / orthostatic problems - Treated with medications known to affect QC/QTc - LV Ejection fraction <40%; LVEF=[SV/EDV] x100 (American Society Echocardiography) - Treated with chronic oral steroids in previous 6 months - Mean SpO2 of < 92% at baseline, taken from average of 3 measurements in each hand - Concurrent disease or condition that in the view of the investigator, would interfere with study participation or safety evaluations, for any reason. |
Country | Name | City | State |
---|---|---|---|
United States | UCSF Benioff Children's Hospital Oakland | Oakland | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability: Incidence of adverse events while treated with vosoritide | Incidence of treatment-emergent adverse events as assessed by the evaluation of vital signs, pulse oximetry, pulmonary function, ECG (cardiac arrhythmia), ECHO (doppler of aortic velocity for stenosis, aortic valve area, and qualitative assessment of aortic valve thickness), spinal X-rays (worsening scoliosis, lordosis or kyphosis), standing lower extremity X-rays (worsening of genu valgum), decrease in six-minute walk distance and linear and segmental growth for determination of excessive or disproportionate growth. All safety assessments will be performed at a minimum at the beginning of the intervention (Visit 1) and the end of the intervention (Visit 3) in patients with MPS IVA and VI | 48 weeks | |
Secondary | Change in height velocity while treated with vosoritide | Explore the change from baseline (0-24 weeks pre-intervention) in age-sex annualized height velocity after 48 weeks of daily subcutaneous vosoritide therapy in patients with MPS IVA and VI | 72 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02294877 -
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
|
||
Completed |
NCT01961518 -
Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome
|
N/A | |
Completed |
NCT01515956 -
Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
|
Phase 2 | |
Recruiting |
NCT05284006 -
Non-invasive Functional Assessment and Pathogenesis of Morquio A
|
||
Completed |
NCT01415427 -
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
|
Phase 3 | |
Recruiting |
NCT04532047 -
In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases
|
Phase 1 | |
Completed |
NCT01920828 -
Gait Analysis in MPS IVA
|
||
Terminated |
NCT01697319 -
Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation
|
Phase 2 | |
Terminated |
NCT01609062 -
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
|
Phase 2 | |
Approved for marketing |
NCT01858103 -
BMN 110 US Expanded Access Program
|
N/A |